Latest Biotech News

Eli Lilly agreed to acquire exclusive worldwide rights to MeiraGTx’s AAV‑AIPL1 gene therapy for Leber congenital amaurosis 4 (LCA4), paying $75 million up front and up to $400 million in...

Two related updates from EnGene/Engene reinforced plans for a biologics license application in high‑risk, BCG‑unresponsive non‑muscle‑invasive bladder cancer. The companies reported additional...

The CRISPR therapeutics sector reported divergent news this week: positive clinical data for a CRISPR‑based cholesterol treatment contrasted with a fatal adverse event in Intellia’s MAGNITUDE...

Beacon Biosignals closed an $86 million financing to build a large, standardized brain‑wave database intended to accelerate neurological drug and diagnostic development. The company plans to...

MGI Tech signed an MoU with South African research and government bodies to sequence up to 110,000 genomes and establish the country’s first national genomic reference. The program installs MGI’s...

Eli Lilly agreed to a $1.2 billion partnership with Suzhou Sanegene Bio to access tissue‑selective RNAi delivery platforms for metabolic disease programs, including obesity. The transaction gives...

Third‑quarter sales of GLP‑1 receptor agonists exceeded $20 billion, driven by strong demand for Lilly’s Mounjaro and new entrants such as Zepbound. The data, compiled by BioCentury, underscore...

The FDA appointed longtime oncology regulator Richard Pazdur to lead the Center for Drug Evaluation and Research (CDER). The change comes after George Tidmarsh’s abrupt departure and aims to...

Eli Lilly agreed to acquire global rights to MeiraGTx’s AAV-AIPL1 gene therapy for Leber congenital amaurosis 4 and struck an expanded AI drug-discovery collaboration with Insilico Medicine. Lilly...

Pfizer won the bidding war for obesity developer Metsera with an amended agreement valuing the company at about $10 billion. Novo Nordisk withdrew from further bidding after a week-long contest....

The FDA announced actions to remove or narrow long-standing black box warnings from hormone replacement therapies used for menopause. Agency leaders said the earlier warnings overstated...

Neurocrine Biosciences reported that NBI‑1070770, a compound licensed from Takeda for major depressive disorder, did not meet its primary endpoint in a Phase 2 study. The company said the drug was...

Engene Holdings released additional preliminary pivotal‑cohort data from its Phase II Legend trial of detalimogene voraplasmid in high‑risk, BCG‑unresponsive non‑muscle invasive bladder cancer...

Gene‑editing firm Metagenomi announced a restructuring that cut roughly 25% of its staff, including the CEO, to focus resources on its preclinical hemophilia A program. The move accompanies new...

The CRISPR sector reported sharply divergent news within days: one firm announced positive early in‑human cholesterol‑lowering data while another disclosed a patient death tied to an ongoing...

Beacon Biosignals closed an $86 million financing to build a large brain‑wave repository aimed at accelerating discovery of neurological disease diagnostics and therapeutics. The company plans to...

Spatial‑omics firm Nucleai signed a collaboration with the University of Glasgow to identify and validate predictive biomarkers for colorectal cancer and advanced polyp risk using multimodal...

Eli Lilly agreed to acquire exclusive global rights to MeiraGTx’s AAV‑AIPL1 gene therapy for Leber congenital amaurosis 4 (LCA4), paying $75 million up front with up to $400 million in milestones....

Pfizer won a competitive bidding process for obesity drug developer Metsera, signing an amended agreement valuing the company at roughly $10 billion. The acquisition brings Metsera’s...

The U.S. Food and Drug Administration announced steps to remove longstanding boxed warnings from hormone replacement therapy (HRT) products used for menopause, concluding prior label language...